Navigation Links
Fuisz Pharma LLC Announces Acquisition of Dysmenorrhea Treatment
Date:4/18/2011

MIAMI, April 18, 2011 /PRNewswire/ -- Fuisz Pharma announced that it has secured an exclusive license for a vaginal treatment of dysmenorrhea. The exclusive license covers existing clinical work whereby a medicated tampon was used to deliver keterolac and it includes two issued United States patents.

Joseph Fuisz, Managing Partner of Fuisz Pharma, stated, "We are pleased to announce this acquisition, having had a long standing interest in vaginal drug delivery, and in particular in the exciting patent portfolio originated by UMD prior to its acquisition by Femina Pharma."

"We look forward to seeking a marketing partner for this treatment.  The existing oral methods are not satisfactory and we believe that the market is finally taking notice of consumer acceptance of vaginal delivery."

The Fuiszes currently have a personal, majority position in Femina Pharma.  Prior to Femina's acquisition of UMD's assets, they had concluded an earlier license of UMD's technology.

Joseph Fuisz continued: "We see an exciting future for Femina's vaginal drug delivery portfolio, through the licensed technology as well as through recent allowances in the anti viral area in which vaginal delivery has interesting applications.  Vaginal delivery of anti virals is particularly exciting in view of limited absorption of many of these compounds when administered orally."

About Fuisz Pharma:

Fuisz Pharma (www.fuisz.com) is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
3. FUISZ Announces Advances in Devices and Solid Dosage Form
4. Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
5. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
6. Fuisz Pharma Releases Clinical Photos of Its Opioid Abuse Detection System
7. Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced it has earned a spot ... 2017" list. The Company was ranked among 500 U.S. ... Employers and Healthcare Equipment and Services. The ... on an anonymous, independent survey of over 30,000 employees ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as ... production of the series is on hiking in American. Viewers can reconnect with America ... great benefits of hiking. , Many consumers have looked for an inventive new place ...
(Date:5/26/2017)... ... ... FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his faith in ... authors, Bob and Margaret Massey. Bob Massey is small in stature but big in ... His love for others is apparent in all of his life decisions. , ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the ... is the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist ... Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ™, ... has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ... secure cloud platform for medical image management. At the core is patented streaming ...
Breaking Medicine News(10 mins):